Novel systemic therapies for the treatment of psoriasis

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 1, 2016, Pages 79-92

  Tan, Ki Wei ^a,b   Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

biologic; IL 17; IL 23; JAK inhibitor; novel; phosphodiesterase 4 inhibitor; psoriasis; small molecules; systemic

Indexed keywords

ABT 122; BI 655066; BIOSIMILAR AGENT; BRODALUMAB; CERTOLIZUMAB PEGOL; FUMARIC ACID DIMETHYL ESTER; GAMMA INTERFERON; GOLIMUMAB; GUSELKUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 23; IXEKIZUMAB; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; METHOTREXATE; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN TYROSINE KINASE; SECUKINUMAB; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TILDRAKIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; JANUS KINASE; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; CYTOKINE PRODUCTION; DENDRITIC CELL; DEPRESSION; DERMATOLOGY LIFE QUALITY INDEX; DIZZINESS; DRUG EFFICACY; DYSPNEA; ENDOTHELIUM CELL; ESOPHAGUS CANCER; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HEADACHE; HEART INFARCTION; HERPES ZOSTER OPHTHALMICUS; HISTOPLASMOSIS; HUMAN; INJECTION SITE REACTION; INTRACELLULAR SIGNALING; KERATINOCYTE; LUNG CANCER; LUNG TUBERCULOSIS; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; MUCOCUTANEOUS CANDIDIASIS; NEUTROPENIA; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROSTATE CANCER; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SUICIDAL IDEATION; SYSTEMIC THERAPY; TH1 CELL; TH17 CELL; TOXOPLASMOSIS; UPPER RESPIRATORY TRACT INFECTION; UTERINE CERVIX CARCINOMA IN SITU; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; DIMETHYL FUMARATE; HUMANS; JANUS KINASES; PHOSPHODIESTERASE 4 INHIBITORS; PSORIASIS;

EID: 84955697351     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1109636     Document Type: Review

References (102)

1. Parisi R, Symmons D, Griffiths CE. (On behalf of IMPACT team). Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385.
2. Wu Y, Mills D, Bala M. Psoriasis: Cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol. 2008;7 (4):373-377.
3. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29(1):10-15.
4. Ficco HM, Citera G, Cocco JA. Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. Clin Rheumatol. 2014;33 (10):1489-1493.
5. Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety and suicidality in patients with psoriasis: A population-based cohort study. Arch Dermatol. 2010;146(8):891-895.
6. Sterry W, Strober BE, Menter A. International Psoriasis Council. Obesity in psoriasis: The metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649-655.
7. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: A systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433-442. discussion 442-3.
8. Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: A systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):12-29.
9. Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: Cohort study using the clinical practice research datalink. J Invest Dermatol. 2015. [Epub ahead of print]. DOI:10.1038/jid.2015.87.
10. Heller MM, Wong JW, Nguyen TV, et al. Quality-of-life instruments: Evaluation of the impact of psoriasis on patients. Dermatol Clin. 2012;30(2):281-291.
11. Vanderpuye-Orgle J, Zhao Y, Lu J. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72:961-967.
12. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271.
13. Tsoi LC, Spain SL, Ellinghaus E, et al. Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nat Commun. 2015;6:7001.
14. Yin X, Low HQ, Wang L. Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility. Nat Commun. 2015;6:6916.
15. Chandran V. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44(2):149-156.
16. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58 (5):826-850.
17. Albanesi C, De Pita O, Girolomoni G. Resident skin cells in psoriasis: A special look at the pathogenetic functions of keratinocytes. Clin Dermatol. 2007;25:581-588.
18. Girolomoni G, Mrowietz U, Paul C. Psoriasis: Rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717-724.
19. Lynde C, Poulin Y, Vender R. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol, 2014;71:141-150.
20. Lowes M, Russell C, Martin D, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 2013;34(4):174-181.
21. Gaffen SL. Structure and signaling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556-567.
22. Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129:2175-2183.
23. Palanivel JA, Macbeth AE, Chetty NC, et al. An insight into JAK-STAT signalling in dermatology. Clin Exp Dermatol. 2014;39(4):513-518.
24. Rawlings JS, Rosler KM, Harrison AD. The JAK/STAT signalling pathway. J Cell Sci. 2004;117:1281-1283.
25. Serezani CH, Ballinger MN, Aronoff DM, et al. Cyclic AMP: Master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39:127-132.
26. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. 2004;84:137-167.
27. Sanz MJ, Cortijo J, Morcillo EJ. PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther. 2005;106(3):269-297.
28. Schafer PH. Targeting PDE4 with apremilast, an orally available specific PDE4 inhibitor, in clinical trials for the treatment of psoriasis and arthritis. Presented at the International Congress on Autoimmunity; 2012 May 9-13; Granada, Spain.
29. Schafer P, Robert M. Novel systemic drugs for psoriasis: Mechanism of action for apremilast, a specific inhibitor of PDE4. J Am Acad Dermatol. 2013;68(6):1041-1042.
30. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-1590.
31. Novartis Press Release. Novartis Cosentyx ™ receives positive CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients. 2014 Nov 21.
32. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.
33. Mrowietz U, Leonardi C, Girolomoni G, et al. Secukinumab retreatment-asneeded versus fixed interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, non-inferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27-36. e1. Epub 2015 May 14. DOI:10.1016/j. jaad.2015.04.011.
34. Thaçi D, Blauvelt A, Reich K. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015. [Epub ahead of print]. pii: S0190-9622(15)01683-7. DOI:10.1016/j.jaad.2015.05.013.
35. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190-1199.
36. Gordon K, Leonardi C, Lebwohl M, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71:1176-1182.
37. Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148-1155.
38. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet. 2015. [Epub ahead of print]. pii: S0140-6736(15) 60125-8. DOI:10.1016/S0140-6736(15) 60125-8.
39. Papp K, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181-1189.
40. Papp K, Menter A, Strober B, et al. Efficacy and safety of brodalumab in subpopulations of patients with difficult-totreat moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2015;72(3):436-439. e1.
41. Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: Results of amagine-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12. Poster session (275): The 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20-24; San Francisco, CA.
42. Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71:1183-1190.
43. Amgen Press release. Amgen to Terminate Participation in Co-development and Commercialization of Brodalumab. 2015 May 22.
44. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-1328.
45. Papp K, Reich K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and safety trial evaluating the effects of apremilast in psoriasias [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37-49.
46. Paul C, Crowley J, Cather J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3 randomized, controlled trial (ESTEEM 2). Poster session: The American Academy of Dermatology 72nd Annual Meeting; 2014 Mar 21-25; Denver, CO.
47. Korman N, Poulin Y, Griffiths CEM, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Pooled 16-week efficacy in patient subgroups (ESTEEM 1 and 2). Poster session (1099): The 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20-24; San Francisco, CA.
48. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-1026.
49. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42:479-488.
50. Celgene Corporation press release. Oral Otezla (apremilast) approved by the U.S. Food and Drug Administration for the treatment of patients with moderate to severe plaque psoriasis. 2014 Sept 23.
51. Reich K, Soung J, Gooderham M, et al. Efficacy and safety of apremilast or etanercept compared with placebo in patients with moderate to severe psoriasis. Latebreaking research: Therapeutic (F010): Presented at the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20-24; San Francisco, CA.
52. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A phase 2b randomized placebocontrolled dose-ranging study. Br J Dermatol. 2012;167:668-677.
53. Mamolo C, Harness J, Tan H, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2014;28 (2):192-203.
54. Bachelez H, Van De Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial. Lancet. 2015;386:552-561.
55. Strober B, Buonanno M, Clark JD, et al. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol. 2013;169(5):992-999.
56. Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two, randomised, placebo-controlled, phase 3 trials. Br J Dermatol. 2015. [Epub ahead of print]. DOI:10.1111/bjd.14018.
57. Van Roon EN, Van De Laar MA. Methotrexate bioavailability. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S27-S32.
58. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford). 2010;49:2337-2345.
59. Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B. Oral vs subcutaneous lowdose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia. 2009;47:207-211.
60. Litjens NH, Nibbering PH, Barrois AJ, et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol. 2003;148:444-451.
61. Arbiser JL. Fumarate esters as angiogenesis inhibitors: Key to action in psoriasis? J Invest Dermatol. 2011;131(6):1189-1191.
62. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT01815723, a randomised, double blind, double dummy, active comparator and placebo controlled confirmative non-inferiority trial of FP187 compared to Fumaderm® in moderate to severe plaque psoriasis; [cited 2015 Jul 22]. Available from: Https://clinicaltrials. gov/ct2/show/NCT01815723.
63. Blauvelt A, Lebwohl M, Bissonnette R. IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. 2015. [Epub ahead of print]. DOI:10.1038/jid.2015.144.
64. Bustamante J, Boisson-Dupuis S, Jouanguy E, et al. Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases. Curr Opin Immunol. 2008;20(1):39-48.
65. Akahoshi M, Nakashima H, Miyake K, et al. Influence of interleukin-12 receptor ?1 polymorphisms on tuberculosis. Hum Genet. 2003;112(3):237-243.
66. Godinez I, Keestra AM, Spees A, et al. The IL-23 axis in Salmonella gastroenteritis. Cell Dmicrobiol. 2011;13(11):1639-1647.
67. Ma CS, Chew GY, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205:1551-1557.
68. Yang B, Kang H, Fung A, et al. The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014;2014:623759.
69. He D, Li H, Yusuf N, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloidderived suppressor cells. J Immunol. 2010;184(5): 2281-2288.
70. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 2009;9 (11):798-809.
71. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21(1):11-19.
72. Alshaker HA, Matalka KZ. IFN-?, IL-17 and TGF-? involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int. 2011;11:33.
73. Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol, 2012;148(11):1244-1250. DOI:10.1001/archdermatol.2012.2502.
74. Erratum in: Arch Dermatol 2013 Feb;149 (2):158. DOI: Http://dx.doi.org./10.1001/jamadermatol.2013.3334.
75. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: A Danish real-world cohort study. J Intern Med. 2013;273(2):197-204. DOI:10.1111/j.1365-2796.2012.02593.x.
76. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials. JAMA. 2011;306(8): 864-871.
77. Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: A cohort study. Br J Dermatol. 2011;165 (5):1066-1073.
78. Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses. J Am Acad Dermatol. 2013;68(5):863-865.
79. Tzellos T, Kyrgidis A, Zouboulis CC. Reevaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013;27(5):622-627.
80. Puig L. Cardiovascular risk and psoriasis: The role of biologic therapy. Actas Dermosifiliogr. 2012;103(10):853-862.
81. Simon T, Taleb S, Danchin N. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570-577.
82. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med. 2009;71:171-186.
83. Shelton RC, Miller AH. Inflammation in depression: Is adiposity a cause? Dialogues Clin Neurosci. 2011;13(1):41-53.
84. Hunter HJ, Hinz R, Gerhard A, et al. Brain inflammation and psoriasis: A [11C]-(R)-PK11195 positron emission tomography study. Br J Dermatol. 2015. [Epub ahead of print]. DOI:10.1111/bjd.13788.
85. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976-986.
86. Kavanaugh A, McInnes I, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73 (9):1689-1694.
87. National Cancer Institute. The surveillance, epidemiology, and end results (SEER) database; 2004 [cited 2013 Jul 22]. Available from: Http://seer.cancer.gov/statistics.
88. Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: Results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180-190.
89. Gordon KB, Duffin KC, Bissonnette R, et al, A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2): 136-144.
90. Papp K, Thaçi D, Reich K. Tildrakizumab (MK-3222), an anti-IL-23p19 monoclonal antibody, improves psoriasis in a phase 2b randomized placebo-controlled trial. Br J Dermatol. 2015. [Epub ahead of print]. DOI:10.1111/bjd.13932.
91. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Mar 11. [Epub ahead of print]. pii: S0091-6749(15)00108-6 DOI:10.1016/j. jaci.2015.01.018.
92. Papp KA, et al. Efficacy and safety of different dose regimens of a novel selective IL-23p19 inhibitor (BI-655066) compared with ustekinumab in patients with moderate-to-severe plaque psoriasis. Abstract F010.2. The 73rd Annual Meeting of the American Academy of Dermatology; 2015 March 20-24; San Francisco, CA.
93. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Identifier NCT02349451, a phase 2 study to investigate the safety, tolerability and efficacy of ABT-122 in subjects with active psoriatic arthritis who have an inadequate response to methotrexate [cited 2015 Sept 25]. Available from: Https://clinicaltrials. gov/ct2/show/NCT02349451.
94. Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in patients with chronic plaque psoriasis: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;384(9959): 2036-2045.
95. Strober BE, Armour K, Romiti R, et al. Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. J Am Acad Dermatol. 2012;66 (2):317-322.
96. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42(4):177-183. Epub 2014 Jun 21.
97. Jung YS, Park DI, Kim YH. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2015. [Epub ahead of print]. DOI:10.1111/jgh.12997.
98. McKeage K. A review of CT-P13: An infliximab biosimilar. BioDrugs. 2014;28 (3):313-321.
99. ClinicalTrials.gov. A service of the U.S. National Institutes of Health; 2014 [cited 2015 July 10]. Available from: Https://clinicaltrials.gov/.
100. Nikamo P, Lysell J, Ståhle M. Association with genetic variants in the IL-23 and NF-?B pathways discriminates between mild and severe psoriasis skin disease. J Invest Dermatol. 2015;135(8):1969-1976. Epub 2015 Mar 19. DOI:10.1038/jid.2015.103.
101. Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169(2):458-463.
102. Julià M, Guilabert A, Lozano F, et al. The role of Fc? receptor polymorphisms in the response to anti-tumor necrosis factor therapy in psoriasis A pharmacogenetic study. JAMA Dermatol. 2013;149(9):1033-1039.